1. Home
  2. KLAR vs COGT Comparison

KLAR vs COGT Comparison

Compare KLAR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KLAR

Klarna Group plc Ordinary Shares

HOLD

Current Price

$16.48

Market Cap

5.5B

Sector

Finance

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$32.73

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLAR
COGT
Founded
2005
2014
Country
United Kingdom
United States
Employees
2831
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.9B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KLAR
COGT
Price
$16.48
$32.73
Analyst Decision
Buy
Strong Buy
Analyst Count
16
15
Target Price
$38.00
$36.21
AVG Volume (30 Days)
5.7M
1.4M
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,871,000.00
Revenue This Year
$28.56
N/A
Revenue Next Year
$19.93
$1,733.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.06
$4.80
52 Week High
$47.48
$43.73

Technical Indicators

Market Signals
Indicator
KLAR
COGT
Relative Strength Index (RSI) 61.56 39.66
Support Level $12.77 $14.00
Resistance Level $16.71 $37.69
Average True Range (ATR) 0.93 1.37
MACD 0.19 -0.22
Stochastic Oscillator 93.69 29.22

Price Performance

Historical Comparison
KLAR
COGT

About KLAR Klarna Group plc Ordinary Shares

Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: